IceCure Medical Ltd. has announced the publication of an independent study evaluating its cryoablation system in combination with stereotactic body radiation therapy (SBRT) for the treatment of stage I non-small cell lung cancer (NSCLC) with tumors ≥2 cm. The study, published in the peer-reviewed journal PLOS One, was led by Dr. Hiroaki Nomori and involved researchers from several Japanese medical institutions. Results show that SBRT followed by cryoablation achieved a 5-year overall survival rate of 74%, compared to published rates of 41%-52% for SBRT alone, and similar to the 67%-82% reported for surgery. The clinical study results have already been presented in the published journal article.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO13689) on November 03, 2025, and is solely responsible for the information contained therein.